Melissa A. Lewis

Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.

T. Conlon, B. Byrne, D. Fuller, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.

B. Byrne, D. Fuller, L. DeRuisseau, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease

B. Byrne, T. J. Fraites, I. Zolotukhin, 2004, Development.

Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.

B. Byrne, M. Atkinson, C. Mah, 2005, Human gene therapy.

Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo

T. Conlon, B. Byrne, C. Mah, 2006, Circulation research.

A new method for recombinant adeno-associated virus vector delivery to murine diaphragm.

B. Byrne, C. Mah, T. J. Fraites, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo

T. Conlon, B. Byrne, C. Mah, 2006, Circulation research.

Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

B. Byrne, C. Mah, T. J. Fraites, 2005, Gene Therapy.

Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D.

B. Byrne, K. Campbell, G. Walter, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.